Seawolf Therapeutics Launches With $100 Million and Sanofi Partnership to Advance DNA-Based Medicines in the US
Seawolf Therapeutics launches from stealth with $100M funding and Sanofi deal to advance TRIDENT, its redosable DNA-based LNP delivery platform for new med
Research Desk
Seawolf Therapeutics, a privately held biotechnology company headquartered in San Diego, California, announced its emergence from stealth with USD 100 million raised to advance its proprietary DNA delivery platform, which the company says is designed to transform patient outcomes.
The seed round was led by founding investor Versant Ventures.
Series A Funding to Advance TRIDENT Therapeutics
The Series A financing was co-led by Versant, MPM BioImpact, and Novartis Venture Fund, with participation from Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments, Pathway to Cures (the philanthropic venture arm of the National Bleeding Disorders Foundation), and others.
The company said the funds will be used to advance its portfolio of therapeutics built on its redosable lipid nanoparticle (LNP)-based DNA delivery system, known as TRIDENT.
Multi-Target Partnership With Sanofi
Alongside the financing announcement, Seawolf unveiled a multi-target research collaboration and exclusive license agreement with Sanofi to develop undisclosed therapies for bleeding disorders and additional unnamed indications.
Under the terms of the deal, Seawolf is eligible for up to USD 1.2 billion in research, development, and commercial milestones, as well as tiered royalties on sales of any products resulting from the collaboration.
"Seawolf is charting a new course in patient care through LNP-based DNA medicines," said Elizabeth Alcamo, Ph.D., president and CEO of Seawolf.
"With a strong syndicate of investors and our collaboration with Sanofi, we are well-positioned to execute on our next stage of growth, which will include advancing our lead program for metabolic diseases and collaborating with Sanofi in its mission to develop therapies for patient unmet needs."
The TRIDENT Platform
The company's technology, TRIDENT (Targeted RNA-Induced DNA Expression via Nuclear Translocation), is a redosable lipid nanoparticle-based DNA delivery system.
According to Seawolf, the platform matches the potency, redosability, safety, and scalability of RNA-based LNP therapies but overcomes their short-lived expression by delivering DNA-based payloads.
The TRIDENT system consists of a proprietary LNP carrying an immune-quiet DNA that encodes a therapeutic transgene, along with an auxiliary factor that facilitates nuclear access. Seawolf says therapies built with the technology are potent, durable, and have a clean safety profile in primates and, unlike virus-based DNA platforms, are redosable, providing the ability to fine-tune or supplement dosing through repeat administration.
The platform has generated sustained protein expression above therapeutic levels in primates at doses that are safe and well-tolerated, according to the company. TRIDENT can be deployed across a broad range of therapeutic areas, including replacing mutant genes and expressing biologics systemically.
Seawolf has demonstrated proof of concept of the technology's applicability in both primates and murine preclinical models of metabolic and rare diseases.
Pipeline and Leadership Outlook
Seawolf's lead proprietary program, targeting metabolic diseases, is advancing to Development Candidate.
"Nucleic acid-based therapies have advanced dramatically over the past decade," said Tom Woiwode, Ph.D., managing director at Versant and chair of Seawolf's board of directors.
"The Seawolf team is now delivering on the promise of using DNA to drive robust and long-term expression of therapeutic proteins directly from the patient's own cells. I look forward to seeing this groundbreaking technology transform treatment options for patients."
The company describes its technology as achieving the delivery of DNA into the nucleus of cells to enable long-term, stable expression of therapeutic proteins in a non-immunogenic and redosable format.
In addition to Versant Ventures, MPM BioImpact, and Novartis Venture Fund, Seawolf is backed by Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments, and Pathway to Cures.
Tracked in the database
Biotechnology Financing and Partnership News · North America
Biotechnology Financing and Partnership News
North America
Chemical
16 November 2026
3 min read
Tagged
Also read
Biocon Secures European Commission Approval for Pertuzumab Biosimilar Pebrilzo in HER2-Positive Breast Cancer
Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany
LOTTE Biologics Signs First Commercial Manufacturing Agreement for Songdo Plant 1 in South Korea
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.